Saturday, July 3, 2021

Artios, Novartis form cancer therapies collaboration

Artios Pharma and Novartis have formed a global research collaboration to discover and validate next generation DNA damage response (DDR) targets to enhance the Swiss drugmaker’s radioligand therapies (RLT).

Novartis’ RLT delivers targeted radiation to a specific subset of cancer cells, thus reducing harmful effects of treatment on the surrounding healthy cells. The firms note that RLT has been shown to improve overall survival and quality of life, particularly in cancers with bone metastases.

Under the three-year deal, Artios and Novartis will perform target discovery and validation, and Novartis will select up to three exclusive DDR targets, receiving worldwide rights to use them with its RLTs.

On the financial side, Novartis will make an upfront payment of $20 million and provide near term research funding to support the collaboration, while Artios stands to receive up to $1.3 billion in discovery, development, regulatory and sales-based milestones, in addition to royalty payments on net sales of products making it to market.

“This collaboration expands the reach of our discovery platform, leveraging our DDR expertise and target knowledge to enhance the potential of radioligand therapies,” commented Dr Niall Martin, Artios’ chief executive.

“From a strategic perspective, this collaboration is an ideal fit which maximises the application of our platform to areas beyond our current focus as we independently advance our pipeline of novel DDR candidates.”

The collaboration does not include Artios’ lead programs, ART0380, which is currently in clinical development, or ART4215, a first-in-class Pol Theta inhibitor.

Source link

Stay Connected


Latest Articles

Covid’s second wave proves lethal for pregnant women

At SVP Hospital in Ahmedabad – one of the major Covid-19 hospitals of the city – 148 pregnant women with Covid-19 infection were admitted...

7 Tips to Keep Your Gut Healthy

This is common to say health (and illness) starts in your gut. If you have poor gut health, you’ll experience anything from wrinkled skin, to...

SII making first batch of Covovax: Poonawalla

The first batch of Covovax, a Covid-19 vaccine developed by Novavax Inc, is being manufactured at the Serum Institute of India's Pune facility, SII...

Sputnik V is safest among all Covid-19 vaccines, no deaths recorded: Buenos Aires study

A study by the Buenos Aires Ministry of Health to monitor the safety of the Sputnik V vaccine against Covid-19 confirmed on Thursday that...

Telangana caps Covid treatment charges in private hospitals

Hyderabad: The government of Telangana on Wednesday issued orders fixing treatment and investigation charges for Covid-19 in private hospitals.The state government, which had capped...